Natco Pharma’s Q4 net profit sees 5% year-over-year increase, reaching ₹406 crore.
Natco Pharma Ltd, an Indian multinational pharmaceutical company, reported a 5% increase in consolidated net profit for the quarter ended March 31, 2025, with a net profit of ₹406 crore compared to ₹386.3 crore in the same period last year. The company’s quarterly revenue also saw a significant increase of 16% year-over-year, reaching ₹1,287.3 crore from ₹1,110.3 crore in Q4 FY24. This growth was driven by strong performance in key segments.
The company’s EBITDA for the quarter stood at ₹548 crore, a 10.2% increase from the previous year, although the operating margin saw a slight dip at 44.89% compared to 46.55% in Q1FY19. The quarter’s performance was impacted by a ₹50 crore impairment charge in the Crop Health Science division and a ₹25 crore chargeback adjustment related to the company’s US subsidiary. Additionally, the company saw significant growth in research and development expenditures.
For the financial year 2025, Natco Pharma reported its highest-ever annual revenue and profit, with revenue rising 16% year-over-year to ₹4,784 crore and net profit climbing 36% to ₹1,883.4 crore. This growth was driven by robust operational performance and strategic delivery. However, the company has forecast a 20% decline in revenue and a 30% decline in net profit for the next financial year, citing pricing pressure in the US market, geopolitical uncertainties, and increasing research and development expenditures.
Natco Pharma is a leading supplier of oncology generics, cardiology, diabetology, and other pharmaceutical specialty segments at affordable prices. The company produces finished dosage forms, active pharmaceutical ingredients, and agrochemicals, and is based in Hyderabad, India. Despite the forecast decline in revenue and profit, the company remains a significant player in the pharmaceutical industry, with a strong track record of delivering affordable, high-quality products to patients around the world. Overall, Natco Pharma’s performance in FY25 was strong, but the company is cautious about the future due to various external factors.
Empowering Women’s Wellbeing: The Significance of Investing in Female Health on International Day of Action – lupin.com
The International Day of Action for Women’s Health is observed on May 28th every year to raise awareness about the importance of women’s health and well-being. Investing in women’s health is crucial for several reasons. Women play a vital role in the social and economic development of a country, and their health has a significant impact on the overall well-being of their families and communities.
Despite this, women’s health remains a neglected area, with many women facing barriers in accessing healthcare services, particularly in low- and middle-income countries. According to the World Health Organization (WHO), women are more likely to experience poverty, unemployment, and lack of education, which can limit their access to healthcare services. Additionally, women are often expected to prioritize the health and well-being of their families over their own, leading to neglect of their own health needs.
Investing in women’s health is important for several reasons. Firstly, it can lead to significant economic benefits. When women are healthy, they are more productive, and their participation in the workforce increases, contributing to the overall economic growth of a country. Secondly, investing in women’s health can lead to improved health outcomes for their families and communities. Healthy women are better equipped to care for their children, and their health has a positive impact on the overall well-being of their families.
Moreover, investing in women’s health can help address the significant disparities in healthcare that exist between men and women. Women are more likely to experience certain health conditions, such as cervical cancer, breast cancer, and maternal mortality, which can be prevented or treated with access to quality healthcare services. Furthermore, investing in women’s health can help promote gender equality and empower women to make informed decisions about their health and well-being.
To achieve this, governments, healthcare providers, and individuals must work together to address the barriers that women face in accessing healthcare services. This can be achieved by increasing access to affordable and quality healthcare services, promoting education and awareness about women’s health, and supporting policies that promote gender equality and women’s empowerment.
In conclusion, investing in women’s health is crucial for promoting the well-being of women, their families, and communities. It can lead to significant economic benefits, improved health outcomes, and promote gender equality. On this International Day of Action for Women’s Health, we must renew our commitment to prioritizing women’s health and well-being, and work together to address the barriers that women face in accessing healthcare services. By doing so, we can create a healthier, more equitable, and prosperous world for all.
Zydus receives US FDA’s fast track designation for its ALS treatment drug, Unsoflast.
Zydus Lifesciences Ltd. has announced that its experimental drug, Usnoflast, has been granted Fast Track Designation by the US Food and Drug Administration (US FDA) for the treatment of amyotrophic lateral sclerosis (ALS). This designation is given to drugs that treat serious conditions and fill an unmet medical need, providing benefits such as faster approval, priority review, and increased communication with the FDA. Usnoflast is an oral NLRP3 inhibitor designed to treat neuroinflammation associated with ALS, a debilitating and fatal neurodegenerative disease.
The Fast Track Designation comes after the US FDA granted Usnoflast Orphan Drug Designation (ODD), which provides incentives such as tax credits, fee access, and a seven-year market exclusivity period after marketing authorization. The ALS Association has welcomed the designation, highlighting the urgent need for effective treatments for ALS, a disease that is usually fatal within two to five years of symptom development.
Zydus has already conducted a Phase 2(a) trial with 24 ALS patients in India and has received US FDA approval to start a Phase 2(b) trial in ALS patients in the US. Pre-clinical studies have shown promise for Usnoflast in treating neuroinflammation, Parkinson’s disease, multiple sclerosis, and inflammatory bowel disease. ALS affects an estimated 32,000 Americans, with 5,000 new diagnoses each year, and over 30,000 people in Europe, with approximately 75,000 patients in India.
The Fast Track Designation and Orphan Drug Designation have enhanced Zydus’s position in the global neurodegenerative disease treatment sphere. The company is now poised to accelerate the development and review of Usnoflast, bringing hope to patients and families affected by ALS. With its clinical advancement and regulatory milestones, Zydus is making significant strides in addressing the unmet medical needs of patients with neurodegenerative diseases. The company’s efforts have the potential to improve the lives of thousands of people worldwide affected by these devastating diseases.
Consiliul Concurenței constată fapte de concurență neloială la Sun Wave Pharma
The Romanian Competition Council has concluded an investigation into Sun Wave Pharma, a subsidiary of an Indian company, and found that it engaged in unfair competition practices. The company was found to have pressured Geltec Private, an Indian manufacturer, to stop delivering food supplements to Bleu Pharma, a competitor in the Romanian market. This action was deemed to be a contravention of honest practices and had a negative impact on the business environment, destabilizing the activity of market players.
The investigation was launched in 2024 after Bleu Pharma notified the Competition Council of the alleged unfair practices. An unannounced inspection was carried out at the headquarters of Sun Wave Pharma as part of the analysis. The Competition Council has prohibited Sun Wave Pharma from using such practices and has stated that the affected company, Bleu Pharma, can seek compensation through the courts.
According to Law 11/1991 on combating unfair competition, the Competition Council has the authority to order measures to prohibit unfair acts and issue decisions that allow harmed companies to seek compensation. The president of the Competition Council, Bogdan Chirițoiu, stated that the decision aims to promote honest practices and a stable business environment.
The ruling is significant as it highlights the importance of fair competition in the Romanian market. The Competition Council’s decision demonstrates its commitment to protecting companies from unfair practices and promoting a level playing field. Bleu Pharma can now seek compensation for any damages suffered as a result of Sun Wave Pharma’s actions, and the decision may serve as a deterrent to other companies engaging in similar practices. The case is a reminder of the importance of complying with competition laws and regulations to ensure a healthy and competitive business environment.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.